Stay updated with breaking news from Jeffrey Matous. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Barriers to sufficient multiple myeloma treatment are explored.
In their closing thoughts, the panelists discuss financial considerations for treating patients with RRMM.
Building strong support systems from both clinical and personal perspectives can drive optimal patient outcomes.
Panelists discuss relapsed/refractory multiple myeloma treatment regimen strategies.